Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 7/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 4/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | CA9 | Q16790 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6320443 | 1.00 | ADRB1 (0.52) | ADRB1ADRB2ADRB3CYP2D6KMT2A | |
| SCHEMBL6322846 | 0.88 | ADRB2 (0.63) | ADRB1ADRB2ADRB3CYP2D6KMT2A | |
| SCHEMBL6322852 | 0.88 | ADRB2 (0.63) | ADRB1ADRB2ADRB3CYP2D6KMT2A | |
| SCHEMBL6323866 | 0.85 | ADRB2 (0.58) | ADRB1ADRB2ADRB3CYP2D6KMT2A | |
| SCHEMBL6323862 | 0.85 | ADRB2 (0.58) | ADRB1ADRB2ADRB3CYP2D6KMT2A | |
| SCHEMBL11580622 | 0.85 | ADRB1 (0.60) | ADRB1ADRB2ADRB3CYP2D6KMT2A | |
| SCHEMBL6319503 | 0.84 | KMT2A (0.63) | ADRB1ADRB2ADRB3CYP2D6KMT2A | |
| SCHEMBL6319499 | 0.84 | KMT2A (0.63) | ADRB1ADRB2ADRB3CYP2D6KMT2A | |
| SCHEMBL6322829 | 0.83 | ADRB2 (0.54) | ADRB1ADRB2ADRB3CYP2D6KMT2A | |
| SCHEMBL6322832 | 0.83 | ADRB2 (0.54) | ADRB1ADRB2ADRB3CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043371-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
| US-20030181726-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043371-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB3, ADRB2 | ADRB1 1/4885ADRB2 3/4885ADRB3 2/4885 |
| US-20030181726-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB3, ADRB2 | ADRB1 1/4885ADRB2 3/4885ADRB3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.